RUBY sickle‑cell editing normalizes hemoglobin

Sickle cell disease makes red blood cells hard and sticky because hemoglobin, the oxygen-carrying protein inside them, clumps into long fibers. Fetal hemoglobin is the newborn form that does not sickle, so researchers have been trying to switch it back on in adults. (nejm.org) The RUBY trial tested renizgamglogene autogedtemcel, or reni-cel, a treatment made from a patient’s own blood-forming stem cells. Doctors edited those cells with CRISPR-Cas12a, then infused them back after busulfan chemotherapy cleared space in the bone marrow. (nejm.org) (aabb.org) The edit targeted the promoters of HBG1 and HBG2, the DNA control switches for the gamma-globin genes that make fetal hemoglobin. Specifically, it disrupted BCL11A binding sites, blocking the protein that normally shuts fetal hemoglobin off after birth. (nejm.org) (cancernetwork.com) The main news is the clinical result: New England Journal of Medicine published the phase 1–2 RUBY data in April 2026. As of the October 29, 2024 cutoff, 28 patients with severe sickle cell disease had received reni-cel. (nejm.org) Among 18 patients with at least six months of follow-up, mean total hemoglobin rose from 9.8 grams per deciliter at baseline to 13.8 grams per deciliter at month 6. Mean fetal hemoglobin rose from 2.5% to 48.1%, and those levels stayed at or above that range afterward. (nejm.org) The trial also tracked the painful blockages that define severe sickle cell disease. Twenty-seven of 28 treated patients had no severe vaso-occlusive events after infusion during the observation period, which is 96.4% of the group. (nejm.org) (insideprecisionmedicine.com) Blood recovery after the transplant-style procedure was measured in days, not months. Among 27 patients with engraftment by cutoff, neutrophils recovered after a median of 23 days and platelets after a median of 25 days. (nejm.org) The safety picture looked like what doctors already expect from busulfan conditioning and autologous stem-cell transplantation, rather than a new pattern tied to the edit itself. The paper says the study was terminated early after the sponsor reassessed development priorities, and the reported analysis was not prespecified. (nejm.org) (aabb.org) Reni-cel joins a field that already has approved gene therapies, including one lentiviral treatment and one CRISPR-Cas9 treatment that edits a different control region linked to BCL11A. RUBY’s approach edits the gamma-globin promoters directly, closer to the switch that keeps fetal hemoglobin off. (cancernetwork.com) (nejm.org) That matters because fetal hemoglobin acts like a built-in anti-sickling shield, and people who naturally keep more of it often have milder disease. The broader burden is large: a 2025 New England Journal of Medicine review said more than 500,000 babies are born with sickle cell disease each year worldwide. (nejm.org) The catch is that this is still an individualized, transplant-center treatment that requires stem-cell collection, gene editing, and high-dose chemotherapy. That means the science moved faster than the practical question of who can actually get it. (nejm.org) (aabb.org) RUBY shows what happens when doctors flip the hemoglobin switch back toward its newborn setting: hemoglobin rises, fetal hemoglobin floods back, and sickle crises mostly disappear in early follow-up. The next test is whether those results hold up over longer follow-up and reach patients beyond a handful of specialized centers. (nejm.org 1) (nejm.org 2)